advertisement
Fechtner R 8
Showing records 1 to 8 | Display all abstracts from Fechtner R122571 A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study
Mansberger SL
Contemporary Clinical Trials 2024; 147: 107730
123186 Settings and effectiveness of the revised probe compared to the original probe for micropulse transscleral cyclophotocoagulation
Hadjokas N
Lasers in Medical Science 2024; 39: 136
122571 A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study
Fechtner R
Contemporary Clinical Trials 2024; 147: 107730
123186 Settings and effectiveness of the revised probe compared to the original probe for micropulse transscleral cyclophotocoagulation
Dosakayala N
Lasers in Medical Science 2024; 39: 136
122571 A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study
Lopez K
Contemporary Clinical Trials 2024; 147: 107730
123186 Settings and effectiveness of the revised probe compared to the original probe for micropulse transscleral cyclophotocoagulation
Alpert S
Lasers in Medical Science 2024; 39: 136
122571 A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study
Hubatsch D
Contemporary Clinical Trials 2024; 147: 107730
123186 Settings and effectiveness of the revised probe compared to the original probe for micropulse transscleral cyclophotocoagulation
Ganapathy P; Fechtner R
Lasers in Medical Science 2024; 39: 136
